New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development
Clinical studies show that immunogenicity observed against therapeutic proteins can limit efficacy and reduce the safety of the treatment. It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic. Studies using deimmunized proteins have...
Gespeichert in:
| Veröffentlicht in: | Drugs in R&D 2008-01, Vol.9 (6), p.385-396 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 396 |
|---|---|
| container_issue | 6 |
| container_start_page | 385 |
| container_title | Drugs in R&D |
| container_volume | 9 |
| creator | Perry, Laura C. A. Jones, Timothy D. Baker, Matthew P. |
| description | Clinical studies show that immunogenicity observed against therapeutic proteins can limit efficacy and reduce the safety of the treatment. It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic. Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.
In silico, in vitro, ex vivo
and
in vivo
methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins. A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential. |
| doi_str_mv | 10.2165/0126839-200809060-00004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_proquest_miscellaneous_69761133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1614375851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-84490d1d0534a9377029e34ac92f34adb0c1c49cfcbdf64898b1c7fd90779b423</originalsourceid><addsrcrecordid>eNqFkTlPxDAQhS0EYrn-AkQUdAE79vooEbeEAKGlthJnAl4ldrATEP8e7yGQaHAzU3zveWYeQkcEnxaET88wKbikKi8wllhhjnOcHttAO4QIlXOFyeayZ_lUSj5BuzHOE0Eol9toQqSSSim8g14f4DM77_vgS_MGMRt89hSgtmaw3mW-ye66bnSQPUPsvYsrYvYGoexhHKxJtB_AupjVY7DudaE2rXXWlG12CR_Q-r4DN-yjraZsIxys6x56ub6aXdzm9483dxfn97mhUgy5ZEzhmtR4SlmpqBC4UJBao4omlbrChhimTGOquuEsrVERI5paYSFUxQq6h05Wvmmj9xHioDsbDbRt6cCPUXMlOCGUJvD4Dzj3Y3BpNl0UjFPBpiJBYgWZ4GMM0Og-2K4MX5pgvQhCr4PQP0HoZRBJebi2H6sO6l_d-vIJkCsg9ou7Qfj9_z_vbx4ylH4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224637457</pqid></control><display><type>article</type><title>New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development</title><source>Springer Nature OA Free Journals</source><creator>Perry, Laura C. A. ; Jones, Timothy D. ; Baker, Matthew P.</creator><creatorcontrib>Perry, Laura C. A. ; Jones, Timothy D. ; Baker, Matthew P.</creatorcontrib><description>Clinical studies show that immunogenicity observed against therapeutic proteins can limit efficacy and reduce the safety of the treatment. It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic. Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.
In silico, in vitro, ex vivo
and
in vivo
methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins. A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential.</description><identifier>ISSN: 1174-5886</identifier><identifier>EISSN: 1179-6901</identifier><identifier>DOI: 10.2165/0126839-200809060-00004</identifier><identifier>PMID: 18989990</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Animals ; Drug Evaluation, Preclinical - methods ; Epitopes, T-Lymphocyte - immunology ; Forecasting ; Humans ; Internal Medicine ; Medicine ; Medicine & Public Health ; Mice ; Models, Biological ; Pharmacology/Toxicology ; Pharmacotherapy ; Primates ; Proteins - immunology ; Proteins - therapeutic use ; Review Article</subject><ispartof>Drugs in R&D, 2008-01, Vol.9 (6), p.385-396</ispartof><rights>Adis Data Information BV 2008</rights><rights>Copyright Wolters Kluwer Health Adis International 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-84490d1d0534a9377029e34ac92f34adb0c1c49cfcbdf64898b1c7fd90779b423</citedby><cites>FETCH-LOGICAL-c387t-84490d1d0534a9377029e34ac92f34adb0c1c49cfcbdf64898b1c7fd90779b423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.2165/0126839-200809060-00004$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://doi.org/10.2165/0126839-200809060-00004$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41120,42189,51576</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.2165/0126839-200809060-00004$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18989990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perry, Laura C. A.</creatorcontrib><creatorcontrib>Jones, Timothy D.</creatorcontrib><creatorcontrib>Baker, Matthew P.</creatorcontrib><title>New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development</title><title>Drugs in R&D</title><addtitle>Drugs in R D</addtitle><addtitle>Drugs R D</addtitle><description>Clinical studies show that immunogenicity observed against therapeutic proteins can limit efficacy and reduce the safety of the treatment. It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic. Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.
In silico, in vitro, ex vivo
and
in vivo
methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins. A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential.</description><subject>Animals</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Epitopes, T-Lymphocyte - immunology</subject><subject>Forecasting</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Models, Biological</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Primates</subject><subject>Proteins - immunology</subject><subject>Proteins - therapeutic use</subject><subject>Review Article</subject><issn>1174-5886</issn><issn>1179-6901</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkTlPxDAQhS0EYrn-AkQUdAE79vooEbeEAKGlthJnAl4ldrATEP8e7yGQaHAzU3zveWYeQkcEnxaET88wKbikKi8wllhhjnOcHttAO4QIlXOFyeayZ_lUSj5BuzHOE0Eol9toQqSSSim8g14f4DM77_vgS_MGMRt89hSgtmaw3mW-ye66bnSQPUPsvYsrYvYGoexhHKxJtB_AupjVY7DudaE2rXXWlG12CR_Q-r4DN-yjraZsIxys6x56ub6aXdzm9483dxfn97mhUgy5ZEzhmtR4SlmpqBC4UJBao4omlbrChhimTGOquuEsrVERI5paYSFUxQq6h05Wvmmj9xHioDsbDbRt6cCPUXMlOCGUJvD4Dzj3Y3BpNl0UjFPBpiJBYgWZ4GMM0Og-2K4MX5pgvQhCr4PQP0HoZRBJebi2H6sO6l_d-vIJkCsg9ou7Qfj9_z_vbx4ylH4</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Perry, Laura C. A.</creator><creator>Jones, Timothy D.</creator><creator>Baker, Matthew P.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development</title><author>Perry, Laura C. A. ; Jones, Timothy D. ; Baker, Matthew P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-84490d1d0534a9377029e34ac92f34adb0c1c49cfcbdf64898b1c7fd90779b423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Epitopes, T-Lymphocyte - immunology</topic><topic>Forecasting</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Models, Biological</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Primates</topic><topic>Proteins - immunology</topic><topic>Proteins - therapeutic use</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perry, Laura C. A.</creatorcontrib><creatorcontrib>Jones, Timothy D.</creatorcontrib><creatorcontrib>Baker, Matthew P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs in R&D</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Perry, Laura C. A.</au><au>Jones, Timothy D.</au><au>Baker, Matthew P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development</atitle><jtitle>Drugs in R&D</jtitle><stitle>Drugs in R D</stitle><addtitle>Drugs R D</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>9</volume><issue>6</issue><spage>385</spage><epage>396</epage><pages>385-396</pages><issn>1174-5886</issn><eissn>1179-6901</eissn><abstract>Clinical studies show that immunogenicity observed against therapeutic proteins can limit efficacy and reduce the safety of the treatment. It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic. Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.
In silico, in vitro, ex vivo
and
in vivo
methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins. A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>18989990</pmid><doi>10.2165/0126839-200809060-00004</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1174-5886 |
| ispartof | Drugs in R&D, 2008-01, Vol.9 (6), p.385-396 |
| issn | 1174-5886 1179-6901 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69761133 |
| source | Springer Nature OA Free Journals |
| subjects | Animals Drug Evaluation, Preclinical - methods Epitopes, T-Lymphocyte - immunology Forecasting Humans Internal Medicine Medicine Medicine & Public Health Mice Models, Biological Pharmacology/Toxicology Pharmacotherapy Primates Proteins - immunology Proteins - therapeutic use Review Article |
| title | New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A15%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Approaches%20to%20Prediction%20of%20Immune%20Responses%20to%20Therapeutic%20Proteins%20during%20Preclinical%20Development&rft.jtitle=Drugs%20in%20R&D&rft.au=Perry,%20Laura%20C.%20A.&rft.date=2008-01-01&rft.volume=9&rft.issue=6&rft.spage=385&rft.epage=396&rft.pages=385-396&rft.issn=1174-5886&rft.eissn=1179-6901&rft_id=info:doi/10.2165/0126839-200809060-00004&rft_dat=%3Cproquest_C6C%3E1614375851%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224637457&rft_id=info:pmid/18989990&rfr_iscdi=true |